139 related articles for article (PubMed ID: 28697831)
1. [Adverse effects of high-dose methotrexate therapy].
Sun Q; Xie Y; Zhao WH; Hua Y; Wu PH; Li S; Lu XT
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Jul; 19(7):781-785. PubMed ID: 28697831
[TBL] [Abstract][Full Text] [Related]
2. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
[TBL] [Abstract][Full Text] [Related]
3. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
4. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
Barakat S; Assem H; Salama M; Mikhael N; El Chazli Y
J Egypt Natl Canc Inst; 2022 Apr; 34(1):17. PubMed ID: 35434757
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Parenteral Glutamine on Methotrexate-induced Oral Mucositis in Children with Acute Lymphoblastic Leukemia.
Chang YH; Yu MS; Wu KH; Hsu MC; Chiou YH; Wu HP; Peng CT; Chao YH
Nutr Cancer; 2017 Jul; 69(5):746-751. PubMed ID: 28569624
[TBL] [Abstract][Full Text] [Related]
6. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
7. Does vitamin A prevent high-dose-methotrexate-induced D-xylose malabsorption in children with cancer?
Dagdemir A; Yildirim H; Aliyazicioglu Y; Kanber Y; Albayrak D; Acar S
Support Care Cancer; 2004 Apr; 12(4):263-7. PubMed ID: 14767751
[TBL] [Abstract][Full Text] [Related]
8. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
9. [Adverse effects of methotrexate in the treatment of acute lymphoblastic leukemia in Uyghur and Han children].
Hu WW; Nuriding H; Yan M
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Nov; 14(11):852-5. PubMed ID: 23146734
[TBL] [Abstract][Full Text] [Related]
10. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
[TBL] [Abstract][Full Text] [Related]
11. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
[TBL] [Abstract][Full Text] [Related]
12. Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
Oosterom N; Griffioen PH; den Hoed MAH; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
PLoS One; 2018; 13(7):e0199574. PubMed ID: 29985926
[TBL] [Abstract][Full Text] [Related]
13. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
[TBL] [Abstract][Full Text] [Related]
14. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Kantar M; Kosova B; Cetingul N; Gumus S; Toroslu E; Zafer N; Topcuoglu N; Aksoylar S; Cinar M; Tetik A; Eroglu Z
Leuk Lymphoma; 2009 Jun; 50(6):912-7. PubMed ID: 19391036
[TBL] [Abstract][Full Text] [Related]
15. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
Rask C; Albertioni F; Schrøder H; Peterson C
Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate concentrations and associated variability factors in high dose therapy of children with acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Škorić B; Kuzmanović M; Jovanović M; Miljković B; Micić D; Jović M; Jovanović A; Vučićević K
Pediatr Hematol Oncol; 2023; 40(5):446-457. PubMed ID: 37195735
[TBL] [Abstract][Full Text] [Related]
17. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
18. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.
Xu W; Tang Y; Song H; Shi S; Yang S
J Pediatr Hematol Oncol; 2007 Oct; 29(10):688-93. PubMed ID: 17921849
[TBL] [Abstract][Full Text] [Related]
20. Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India.
Dhingra H; Kalra M; Mahajan A
Pediatr Blood Cancer; 2020 Nov; 67(11):e28394. PubMed ID: 32813334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
